We are live on ! Find out more
MCRB icon

Seres Therapeutics

152 hedge funds and large institutions have $1.85B invested in Seres Therapeutics in 2021 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 61 increasing their positions, 45 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

606% more call options, than puts

Call options by funds: $35.3M | Put options by funds: $5.01M

36% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 45

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

0.17% more ownership

Funds ownership: 4.74%4.92% (+0.17%)

0% more funds holding

Funds holding: 152152 (0)

12% less capital invested

Capital invested by funds: $2.12B → $1.85B (-$264M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
152
Holders Change
Holders Change %
0%
% of All Funds
2.67%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
25
Increased
61
Reduced
45
Closed
23
Calls
$35.3M
Puts
$5.01M
Net Calls
+$30.3M
Net Calls Change
+$19.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Jane Street
51
Jane Street
New York
$1.54M -$143K -311 -8%
UBS AM
52
UBS AM
Illinois
$1.48M +$207K +449 +14%
RhumbLine Advisers
53
RhumbLine Advisers
Massachusetts
$1.45M -$116K -251 -7%
LPL Financial
54
LPL Financial
California
$1.34M +$159K +345 +12%
TRCT
55
Tower Research Capital (TRC)
New York
$1.3M +$1.4M +3,048 +2,674%
Deutsche Bank
56
Deutsche Bank
Germany
$1.3M +$399K +866 +38%
Group One Trading
57
Group One Trading
Illinois
$1.28M +$411K +893 +40%
Wells Fargo
58
Wells Fargo
California
$1.25M -$1.33M -2,891 -49%
DekaBank Deutsche Girozentrale
59
DekaBank Deutsche Girozentrale
Germany
$1.25M +$1.5M +3,250 New
Principal Financial Group
60
Principal Financial Group
Iowa
$1.21M +$602K +1,308 +81%
Barclays
61
Barclays
United Kingdom
$1.13M +$722K +1,569 +133%
PAM
62
Panagora Asset Management
Massachusetts
$1.09M +$1.21M +2,636 +23,964%
D.E. Shaw & Co
63
D.E. Shaw & Co
New York
$1.07M -$7.89M -17,144 -87%
New York State Common Retirement Fund
64
New York State Common Retirement Fund
New York
$1.06M -$23K -50 -2%
N
65
Nuveen
North Carolina
$1.03M -$42.4K -92 -0.8%
HP
66
Harbourvest Partners
Massachusetts
$1.02M -$795K -1,727 -41%
SEC
67
Seven Eight Capital
New York
$1M
CS
68
Credit Suisse
Switzerland
$987K -$1.58M -3,430 -59%
TD Asset Management
69
TD Asset Management
Ontario, Canada
$859K +$136K +296 +17%
MWNA
70
Marshall Wace North America
New York
$857K +$958K +2,081 New
BFM
71
Boothbay Fund Management
New York
$840K +$939K +2,040 New
PPA
72
Parametric Portfolio Associates
Washington
$705K +$222K +483 +39%
Simplex Trading
73
Simplex Trading
Illinois
$672K +$495K +1,076 +194%
Manulife (Manufacturers Life Insurance)
74
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$648K -$41.4K -90 -5%
Bank Julius Baer & Co
75
Bank Julius Baer & Co
Switzerland
$623K +$98.1K +213 +16%

MCRB Hedge Fund Activity: Q1 2021 in Review

152 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2021, worth a combined $1.85B — down 12% from $2.12B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new MCRB positions and 23 closed out — a net gain of 2 holders — while 61 added to existing stakes and 45 trimmed.

The largest buyer was RA Capital Management, opening a new position worth an estimated $85.1M. The largest seller was ARK Investment Management, cutting an estimated $43.4M.

  • 152 institutional investors held Seres Therapeutics (MCRB) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $1.85B of Seres Therapeutics stock for Q1 2021, down 12% quarter-over-quarter.
  • 25 funds opened new Seres Therapeutics positions in Q1 2021 and 23 closed out, a net change of +2 holders.
  • The largest Seres Therapeutics buyer in Q1 2021 was RA Capital Management, an estimated $85.1M added.
  • The largest Seres Therapeutics seller in Q1 2021 was ARK Investment Management, an estimated $43.4M sold.

Based on aggregated 13F filings for Q1 2021.